Cost-Minimization of Mabthera Intravenous Versus Subcutaneous Administration

Subcutaneous Vs Intravenous Administration Of Trastuzumab In Her2+ Breast Cancer Patients: A Macedonian Cost-Minimization Analysis.

BACKGROUND • The rising cost of cancer care has progressively become hardly sustainable for health care systems worldwide . • Trastuzumab (Herceptin®) humanized IgG1 monoclonal antibody is standard treatment for patients with early and with metastatic HER2-positive breast cancer. • SC-TRA, co-formulation of TRA with recombinant human hyaluronidase alternative to IV-TRA drug administration for s...

Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

Trastuzumab was the first targeted therapy for HER2 positive breast cancer. It has become the standard of care for HER2 positive metastatic breast cancer since 2000 and in the adjuvant setting since 2006. Adjuvant it is given for a year and in patients with metastatic disease until progression. The standard mode of administration is intravenous. Recently a subcutaneous form has become available...

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

This phase I study compared pharmacokinetics and pharmacodynamics, and assessed safety and efficacy of intravenous and subcutaneous administration of bortezomib. Relapsed or refractory multiple myeloma patients were randomized to receive bortezomib by standard intravenous bolus (n=12) or subcutaneous injection (n=12) at the recommended dose and schedule (1.3 mg/m2, days 1, 4, 8, 11; eight 21-da...

Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients

Cladribine induces durable complete remission (CR) in approximately 85% of hairy cell leukemia (HCL) patients. In Egypt, cladribine is mainly used as IV continuous infusion at a dose of 0.1 mg/kg/day for 7 days and as SC bolus injection at a dose of 0.14 mg/kg/day for 5 days. We aimed to compare the outcome and toxicity between these two regimens. We retrospectively collected data from HCL pati...